Detailansicht

Wissensnetz

Person

Andreas Viardot (1968-)

Name	Andreas Viardot
Zeit	1968- (Lebensdaten)
Akademischer Grad bzw. Titel	Dr. med.
Weitere Angaben	Diss. Medizinische Fakultät an der Universität Ulm (2002); Habil.-Schr. Medizinische Fakultät (Fach Innere Medizin) an der Universität Ulm (2010)
Datensatztyp	Person
GND-Nummer	123546605
Datensatz-ID	123546605
Beteiligt an alle anzeigen Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial Bedeutung des genomischen Screening bei Keimzentrumslymphomen (follikuläre und diffus-großzellige B-Zell-Non-Hodgkin-Lymphome) : Vergleich der prognostischen Relevanz von Bänderungsanalyse, comparativer genomischer Hybridisierung und microarraybasierter Analyseverfahren Sekundäre genetische Aberrationen bei follikulären Lymphomen : Stellenwert von Chromosomenbänderungsanalyse und comparativer genomischer Hybridisierung (CGH)

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Andreas Viardot (1968-)

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia

A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial

UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma

Bedeutung des genomischen Screening bei Keimzentrumslymphomen (follikuläre und diffus-großzellige B-Zell-Non-Hodgkin-Lymphome) : Vergleich der prognostischen Relevanz von Bänderungsanalyse, comparativer genomischer Hybridisierung und microarraybasierter Analyseverfahren

Sekundäre genetische Aberrationen bei follikulären Lymphomen : Stellenwert von Chromosomenbänderungsanalyse und comparativer genomischer Hybridisierung (CGH)